These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 10815920)

  • 1. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):309-14. PubMed ID: 12385965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Mandelbaum-Shavit F; Qazen MM; Zalipsky S
    Bioconjug Chem; 1999; 10(2):289-98. PubMed ID: 10077479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
    Eliaz RE; Szoka FC
    Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
    Leamon CP; Cooper SR; Hardee GE
    Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
    Lu Y; Wu J; Wu J; Gonit M; Yang X; Lee A; Xiang G; Li H; Liu S; Marcucci G; Ratnam M; Lee RJ
    Mol Pharm; 2007; 4(5):707-12. PubMed ID: 17708654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
    Kawano K; Onose E; Hattori Y; Maitani Y
    Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB; Duan J; Sridhar R; Damle BD
    Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES; Na K; Bae YH
    J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
    Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.